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Abstract 
Background: Nitric oxide may have a protective effect on the liver during endotoxemia and chronic 
inflammation. There is evidence that it maintains liver and intestinal tissue integrity during inflammatory 
processes. We evaluated the impact of altering nitric oxide release on acute liver injury, the associated gut 
injury and bacterial translocation, at different time intervals. Methods: An acute rat liver injury model induced 
by D-galactosamine was used. Sprague Dawley rats were divided into four main groups: normal control, acute 
liver injury control, acute liver injury + N-nitro-L-arginine methyl ester (L-NAME), acute liver injury + L-NAME + 
L-arginine. Each group was divided into three subgroups according to the different time intervals (6, 12, 24 
hours) after the induction of the liver injury. Liver enzymes and bilirubin were evaluated, as well as bacterial 
translocation, cecal and colonic microflora, and histological study of liver, ileum and cecum. Results:Liver 
enzymes increased significantly at all time intervals in acute liver injury + L-NAME compared to liver injury 
control groups. Bacterial translocation increased significantly in liver injury + L-NAME groups; at 6 hours to the 
liver, at 12 hours to the liver and mesenteric lymph nodes (MLNs), and at 24 hours to arterial and portal blood, 
liver and MLNS. Inhibition of nitric oxide increased significantly the Enterobacteriaceae count in cecum 
compared to normal and liver injury control groups. The G-negative anaerobes increased significantly in the 
colon compared to the liver injury control group. Conclusion: Inhibition of nitric oxide in an acute liver injury 
model potentiates the liver injury as evidenced by increased appearance of hepatocellular necrosis and 
elevated liver enzymes and bilirubin. It increases the Enterobacteriaceae in both cecum and colon and G-
negative anaerobes in the colon. It also increases bacterial translocation to extra-intestinal sites. The 
increased bacterial translocation could be one of the mechanisms potentiating liver injury and nitric oxide may 
be pathophysiologically involved. Further studies are required to confirm this hypothesis. 
Key Words: Acute liver injury, Arginine, Bacterial translocation, Intestinal microflora, L-NAME, Nitric oxide. 
 
Introduction 
Nitric oxide (NO) is synthesized from L-arginine 
by the enzyme nitric oxide synthase (NOS). Two 
types of NOS have been identified: one is 
constitutive and responsible for the physiological 
transduction purposes and the other is induced by 
cytokines and releases NO as part of the 
immunological response [1]. Macrophages [2,3], 
Kupffer cells [4] and hepatocytes [5] possess the 
inducible NOS. Kupffer cells activated by septic 
stimuli or other inflammatory conditions respond 
by forming NO themselves and by inducing its 
formation in neighbouring hepatocytes [6]. 
Moreover, endotoxin can induce NOS in 
hepatocytes [7].  
The role of endogenous NO on gut function has 
been previously studied. Stark ME,et al , have 
shown that  increase gastric mucosal levels of NO 
by augmenting endogenous NO production or 
providing an exogenous source of NO are effective 
in the prevention of acute gastric mucosal injury in 
high-risk setting [8]. The inhibition of NOS 
facilitates mucosal injury [9] and pre-treatment with 
an inhibitor of NO synthesis enhances endotoxin-
induced small intestinal damage and plasma 
leakage [10]. The endogenous NO is also 
important in the prevention of hypoxia-induced 
intestinal injury [11]. Decreased production and/or 
increased NO inactivation would likely enhance 
intestinal permeability [12].  
One of the roles of NO production in the liver 
[13] and intestine [14] is to maintain tissue integrity 
during inflammatory processes. NO is important in 
mucosal defence in that it influences virtually 
every component of mucosal defence [15]. It has 
been suggested that NO has a protective effect on 
the liver during endotoxemia and chronic 
inflammation [16], as evidenced by reduced 
hepatocellular necrosis and decreased release of 
intracellular liver enzymes when NO production is 
maintained [17]. The protective effect of NO is 
also evidenced by the appearance of 
hepatocellular necrosis in animals in which NO 
production has been blocked [16]. In a model of 
acetaminophen hepatotoxicity, inhibition of 
cytokine-mediated NO production potentiated the 
injury [17] and exogenous delivery of NO 
significantly decreased the acetaminophen-
induced hepatotoxicity [18]. The results of some 
studies support previous reports of a protective 
effect of NO on the liver in endotoxemia and 
suggest that NO may up-regulate hepatic protein 
synthesis in vivo [19]. 
We have previously shown that bacterial 
translocation occurs in D-galactosamine acute 
liver injury [20, 21]. Bacterial infection and sepsis 
are recognized as serious complications of acute 
liver failure with gram-negative enteric bacteria 
being the most frequent causative organisms [22, 
23]. The exact mechanisms of bacterial 
translocation in acute liver injury are unclear. We 
decided to test the hypothesis that NO inhibition 
may potentiate liver injury, bacterial translocation, 
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and that changes in bacterial translocation may 
influence the degree of liver injury. 
The aim of this experiment was to study the role 
of NO in an acute liver injury model induced by D-
galactosamine and to examine the impact of 
bacterial translocation, intestinal mucosal 
changes, endotoxemia, and cecal and colonic 
microflora changes in response to NO 
manipulation and the extent of liver injury. 
 
Materials and methods 
Experimental design: Male Sprague - Dawley 
rats (BK Universal AB, Sollentuna, Sweden), with 
a weight range of 220-300 g were used and 
divided into four main groups (24 rats in each main 
group, 8 rats in each subgroup): normal control 
group, acute liver injury control group, acute liver 
injury + N-nitro-L-arginine methyl ester (L-NAME) 
group and acute liver injury + L-NAME + L-arginine 
group. Each group was divided into three 
subgroups according to the time interval after the 
liver injury (6, 12, 24 hours). The inhibitor of NOS 
which we used in our experiment is NG- nitro-L-
arginine methyl ester (L-NAME), an inhibitor of 
both the constitutive and inducible form of NOS. It 
has been used in many experiments studying the 
effects of NO on the liver. All animals received 
normal rat chow (R3, Lactamin AB, and 
Stockholm, Sweden) and water ad libitum 
throughout the experiment and were kept at 12 
hours light/dark cycle and 22oC room temperature. 
The Animal Ethics Committee of Lund University 
approved the experimental protocol. Acute liver 
injury was induced by intraperitoneal injection of 
D- galactosamine (Sigma Chemicals Co., St. 
Louis, MO, USA) 1.1 g/Kg body wt., [24].  L-NAME 
(Sigma) 100 mg / kg B.W. and L-arginine (Sigma) 
300 mg / kg B.W. were injected intraperitoneally 
half an hour before the liver injury when indicated. 
Samples were collected (6, 12, 24 hours) following 
liver injury. Under ether anaesthesia a laparotomy 
was performed through a midline incision under 
aseptic technique. Portal blood was collected for 
bacteriological tests and measurement of 
endotoxin levels, aortic blood for bacteriological 
and liver enzyme tests. Samples from the caudate 
lobe of the liver, mesenteric lymph nodes (MLNs), 
and cecal and colonic contents were obtained for 
bacteriological counts. Samples from liver, distal 
small intestine and cecum were taken for 
histological examination. 
Bacterial translocation: Blood samples were 
immediately placed in EDTA containing sterile 
tubes. Tissue samples were placed in 5 ml of 
sterile transport medium [25]. Samples were 
placed in ultrasonic bath (Millipore, Sundbyberg, 
Sweden) for 5 minutes and swirled on Chiltern 
(Terma-Glas, Gothenberg, Sweden) for 2 minutes. 
Total aerobic plate count was made by placing 1.0 
ml of the sample on Brain Heart Infusion agar BHI 
(Oxiod, Hampshire, England) and incubated at 
37oC for 3 days. Total anaerobic plate count was 
made by placing the samples on BHI and 
incubating under anaerobic condition (Gas Pack 
System, Gas Pack, Becton Dickenson 
Microbiology Systems, Cockeynsville, MD, USA) 
at 37oC for 3 days. After 3 days the number of 
colonies formed on each plate were counted and 
corrected for the weight of the original tissue. 
Tissue samples were expressed per gram of 
tissue while blood samples were expressed per ml 
of blood. 
Intestinal microflora: Samples taken from cecal 
and colonic content were immediately placed in 5 
ml of sterile transport medium and transferred into 
ultrasonic bath and swirled on chiltern as above. 
After a conventional dilution procedure, viable 
counts were obtained from brain heart infusion 
agar BHI (Difco, Detroit, MI) that was incubated 
aerobically and anaerobically at 37oC for 72 hours 
(aerobic and anaerobic bacterial count, 
respectively). From Rogosa (Oxoid, Hampshire, 
England) and BHI agar containing gram-negative 
anaerobic supplement (Oxoid, Hampshire, 
England) incubated anaerobically at 37oC for 72 
hours (lactobacilli and gram-negative anaerobic 
bacterial counts respectively) and from violet red-
bile-glucose agar VRBG (Oxoid, Hampshire, 
England) incubated aerobically at 37oC for 24 
hours (Enterobacteriaceae counts)  
Liver enzymes and bilirubin: After centrifugation 
of the blood (1000xg, 10 min.) serum bilirubin (Bil), 
alkaline phosphatase (ALP), aspartate 
aminotransferase (ASAT) and alanine 
aminotransferase (ALAT) levels in aortic blood 
were measured according to the 
recommendations of the Committee on the 
Enzymes of the Scandinavian Society for Clinical 
Chemistry and Clinical Physiology [26]. 
Histological study: Samples from the left lobe of 
the liver, distal small intestine and cecum were 
placed in 4% phosphate buffered formaldehyde. 
Paraffin-embedded samples were sliced and 
studied under light microscopy after staining with 
haematoxylin and eosin. At least 3 slides were 
studied from each specimen in a blinded fashion. 
Serum endotoxin: Four ml of portal blood were 
placed in endotoxin free, special sampling tubes 
containing heparin (Endo Tube, Chromogenix, 
Mölndal, Sweden) and centrifuged at 3000 g for 
15 min. at 4oC. The endotoxin level in the 
separated plasma was measured by Limulus 
Amoebocyte Lysate (LAL) using Chromogenix 
Coatest (Chromogenix, Mölndal, Sweden) [27]. 
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The detection limit of endotoxin in our method was 
0.25 units (1.2 EU = 100 pg). Because of the high 
levels of bilirubin in some of the samples, plasma 
blank containing 200￿L of 20% acetic acid was 
used as appropriate. 
 
Statistics 
Values are presented as Mean ± SEM. 
Differences between all groups were evaluated by 
one way ANOVA test followed by all pairwise 
multiple comparison Student Newman-Keuls 
method. The incidence of bacterial translocation 
was evaluated using Fisher's exact Test. 
Probability levels less than 0.05 were considered 
significant (p<0.05). 
 
Table 1 Liver function tests at different time points after 
induction of liver injury 
Time  Grou
ps 
ALP 
(uKat/L) 
Bil 
(umol/L) 
ASAT 
(uKat/L) 
ALAT 
(uKat/L) 
  NC  6.8±1.1 5.7±1.3 2.2±0.4  1.5±0.4 
A  8.8±0.7 7.9±1.6 8.9±0.9  8.3±1.1 
B  14±1.7* 12.6±1* 15±1.3*  12±0.8*  6 
hrs 
C  8.7±0.6◦ 10±0.7◦ 11±1.4◦ 9  ±0.6◦ 
A  10.8±0.3 10.9±0.5 9.8±0.6 6.7±0.7 
B  12.1±0.7 11.2±0.9 13.9±1.3 9.8±0.8  12 
hrs 
C  9.8±0.9 9.2±0.7  9.3±1.4◦ 7±1◦ 
A  16.1±1.4 15.6±1.9 34.6±4.6 20±2.9 
B  20.5±1.2* 30  ±3.5* 72.8±12* 49±11*  24 
hrs 
C  14±0.8◦ 21.1±2◦ 44.5±4◦ 27±2.8◦ 
A: Acute liver injury control group, B:Acute liver injury 
+ L-NAME groups, C:Acute liver injury + L-NAME + L-
arginine groups, NC: normal control. ALP: alkaline 
phosphatase, Bil: bilirubin, ASAT: aspartate 
aminotransferase, ALAT: alanine aminotransferase. * 
denotes P<0.05 compared to group A, ◦ denotes P<0.05 
compared to group B (All pairwise multiple comparisons, 
Newman-Keils method). 
 
Table 2 Incidence of Bacterial translocation in 
experimental groups at different time intervals 
Time Groups    PB  AB  Liver  MLNs 
 NC  0/8  0/8  0/8  0/8 
A 5/8*  3/8 7/8**  7/8 
B 5/8*  5/8*  8/8***  8/8***  6 
hrs  C 5/8*  2/8 7/8***  4/8 
A 5/8*  5/8*  8/8***  8/8*** 
B 7/8**  5/8 8/8***  8/8***  12 
hrs  C 4/8 4/8 8/8***  7/8** 
A 7/8**  8/8***  8/8***  8/8*** 
B 8/8***  8/8***  8/8***  8/8***  24 
hrs  C 4/8 5/8*  6/8**  7/8** 
A: Acute liver injury control group, B:Acute liver injury 
+ L-NAME groups, C:Acute liver injury + L-NAME + L-
arginine groups, NC: normal control. PB: portal blood, 
AB: arterial blood, MLNs: mesenteric lymph nodes. * 
denotes p<0.05, ** denotes p<0.01, *** denotes p<0.001 
compared to normal control. 
 
Table 3 Incidence of Bacterial translocation in 
experimental groups at different time intervals (CFU/g 
tissue of ml blood) 
Ti
me 
Gro
up  PB AB Liver MLNs 
A 20±7  6±3 275±75  335±115 
B 19±9  25±11 920±305*  735±310  6 
hrs  C 15±6  13±10 145±55◦ 325±220 
A 12±8  80±37 255±80  115±20 
B 26±9  135±84  1865± 
740*  680±215*  12 
hrs 
C 10±4  19±9 170±65◦ 140±45◦ 
A 19±10  44±16  4120± 
1495  3770±1225 
B 83±21* 
138± 
36* 
8185± 
1550* 
9070± 
2010* 
24 
hrs 
C 13±7◦  9±3◦ 1550±780◦  3135± 
1280◦ 
A: Acute liver injury control group, B:Acute liver injury 
+ L-NAME groups, C:Acute liver injury + L-NAME + L-
arginine groups, NC: normal control. PB: portal blood, 
AB: arterial blood, MLNs: mesenteric lymph nodes. 
*P<0.05 compared to group A, ◦ P<0.05 compared to 
group B (All pairwise multiple comparisons, Newman-
Keils method). 
 
Table 4 Cecal and colonic microflora count (Log 
CFU/g content) 
Gro
ups 
Total 
aerobic 
Total 
anaerob
ic 
G-ve 
anaerob
ic 
Enterob
acteriac
eae 
lactoba
cilli 
cecaum 
NC 8±0.1 8.2±0.1  8.3±0.1 6.5±0.3  7.9±0.1 
A 8.1±0.1  8.3±0.1  8.1±0.1 6.5±0.3  8.1±0.1
* 
B 8.1±0.1  8.3±0.1  8.2±0.1  7.6 
±0.2*◦ 
8.1±0.1
* 
colon 
NC 8.2±0.1 8.6±0.1 8.6±0.1 4.1  ±1.7 8.4±0.1 
A 8.2±0.1  8.6±0.1  8.5±0.1  7.2  ±0.2*  8.4±0.1 
B 8.2±0.1  8.6±0.1  8.8±0.1◦ 7.9  ±0.3* 8.6±0.1
*◦ 
A: Acute liver injury control group, B:Acute liver injury 
+ L-NAME groups, * denotes P<0.05 compared to group 
NC,  ◦ denotes P<0.05 compared to group A (All 
pairwise multiple comparisons, Newman-Keils method). 
 
Results 
There was no mortality at any time point in any 
of the experimental groups. In the liver injury + L-
NAME groups, the animals appeared sicker with 
retarded locomotion and piloerection than the 
acute liver injury control group. 
 
Liver enzymes and bilirubin: Six hours after 
induction of the liver injury, there was a significant 
increase of the liver enzymes (ALP, ASAT, and 
ALAT) and bilirubin levels in the liver injury + L-
NAME group compared to the liver injury control 
group. In the liver injury + L-NAME + L-arginine 
group the liver enzymes decreased significantly 
compared to liver injury + L-NAME group (Table 
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1). Twelve hours after the liver injury, the liver 
enzymes increased significantly in the liver injury + 
L-NAME group compared to the liver injury control 
group (Table 1). At 24 hours there was a 
significant elevation of liver enzymes and bilirubin 
in the liver injury + L-NAME group compared to the 
liver injury control group, which had been 
decreased significantly after addition of arginine 
(Table 1).  
 
Bacterial translocation: The incidence of 
bacterial translocation, at all time intervals, 
increased in all the experimental groups compared 
to normal control (Table 2). Six hours following 
liver injury the number of translocated bacteria 
differed in the experimental groups. Bacterial 
translocation to the liver increased in the liver 
injury + L-NAME group compared to the liver injury 
control group, and this effect was reversed by the 
addition of arginine. The bacterial translocation 
after 12 hours showed the same finding to the liver 
and MLNs, while after 24 hours the same effect 
was seen in the portal and arterial blood, liver and 
MLNs (Table 3).  
 
Intestinal microflora: In the cecum the 
Enterobacteriaceae count increased significantly in 
the liver injury + L-NAME group compared to 
normal control and liver injury control groups. The 
Lactobacillus count increased significantly in both: 
liver injury and liver injury + L-NAME groups 
compared to normal control. In the colon the G -ve 
anaerobic count increased significantly in the liver 
injury + L-NAME group compared to the liver injury 
control group. While the Enterobacteriaceae count 
increased significantly in the liver injury and liver 
injury + L-NAME groups compared to normal 
control. The Lactobacillus count increased 
significantly in the liver injury + L-NAME group 
compared to the liver injury and normal control 
groups (Table 4). 
 
Histological study: The liver showed more 
hepatocellular necrosis and inflammatory cell 
infiltrations, at all time intervals, in the acute liver 
injury + L-NAME groups compared to the liver 
injury control groups (Figures 1, 2, 3). Samples of 
the distal small intestine and cecum were normal 
and showed no histopathological changes on light 
microscopy in any of the experimental groups 
(data not shown). 
 
Serum endotoxin levels: In all the experimental 
groups the endotoxin levels were below detectable 
levels (<0.25 U). 
 
 
Discussion 
The results of this study showed that inhibition 
of NO synthesis by administration of L -NAME 
significantly increased hepatocellular damage as 
indicated by increased release of liver enzymes.  
 
 
 
 
 
Figure1: Histological appearance of the liver 6 hours 
after the injury (Hematoxylin-Eosin, x100). The liver 
injury control group (Fig. 1A) showing hepatocellular 
necrosis and inflammatory cell infiltration. The liver 
injury + L-NAME group (Fig. 1B) showing more 
hepatocellular necrosis and inflammatory cell infiltration 
compared to the liver injury control group.  
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Figure 2: Histological appearance of the liver 12 hours 
after the injury (Hematoxylin-Eosin, x100). The liver 
injury control group (Fig. 2A) showing hepatocellular 
necrosis and inflammatory cell infiltration. The liver injury 
+ L-NAME group (Fig. 2B) showing more hepatocellular 
necrosis and inflammatory cell infiltration compared to 
the liver injury control group. 
 
This effect was partially reversed by 
simultaneous administration of L-arginine. This 
suggests a possible role for NO in protecting the 
liver in this acute liver injury model. When NO 
production was inhibited at all time intervals 
studied, there was more hepatocellular necrosis 
and inflammatory cell infiltration compared to the 
acute liver injury control groups. The protective 
effect of NO on liver function is in accordance with 
other studies. Kuo et al [17] showed that 
maintenance of NO production during 
endotoxemia and chronic inflammation reduced 
hepatocellular necrosis and decreased release of 
intracellular liver enzymes, while blocking the 
production increased the hepatocellular necrosis.  
 
 
 
 
Figure 3: Histological appearance of the liver 24 
hours after the injury (Hematoxylin-Eosin, x100). The 
liver injury control group (Fig. 3A) showing 
hepatocellular necrosis and inflammatory cell infiltration. 
The liver injury + L-NAME group (Fig. 3B) showing 
more hepatocellular necrosis and inflammatory cell 
infiltration.  
 
In another study, aspartate aminotransferase 
levels were elevated in endotoxemic rats pre-
treated with NO inhibitor [28]. In addition, a liver-
selective NO donor has been used to almost 
completely inhibit liver damage in the LPS-
galactosamine model [29]. It has been shown that 
inhibitors of inducible NOS are more effective than 
an NO donor in reducing carbon-tetrachloride 
induced liver injury (30). 
The liver plays a central role in haemostasis, 
and acute liver failure results in a very complex 
coagulopathy [31]. Hepatic NO from Kupffer cells, 
endothelial cells and hepatocytes may be involved 
in modulating the local circulation by preventing 
platelet aggregation in hepatic sinusoids and 
contributing to increased blood flow [32]. The 
hemodynamic of the hepatic microcirculation is 
known to depend on the activity of smooth muscle 
cells around the arterioles and pre-capillary 
sphincters [33]. The increased hepatic damage 
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from inhibition of NO synthesis is mediated in part 
by superoxide and hydroxyl radicals [16, 34]. It 
could also be due to increased oxygen free radical 
availability following removal of NO as a 
superoxide scavenger [16]. Inhibition of NO 
formation by L-NAME stimulated the release of 
superoxide anion by the liver [35] and NO has 
been shown to inhibit superoxide anion generation 
by neutrophils [36]. We have shown that NO 
inhibition increases the hepatocellular damage and 
the release of the liver enzymes and bilirubin. The 
mechanisms of the protective effect of NO on the 
liver may be due to inhibition of one or several of 
the beneficial effects of NO. These include 
regulation of both arterial tone and blood flow 
[37,38], inhibited platelet aggregation [39] and 
reduced adherence [40], and scavenging of 
superoxide and other oxygen-derived free radicals 
[41].  
The gut is a major reservoir of bacteria, and 
under normal conditions a series of local and 
systemic protective mechanisms prevent passage 
of these potentially pathogenic bacteria beyond 
the intestinal lumen. Severe physiologic alterations 
may affect these mechanisms, favouring 
translocation of enteric bacteria across the 
intestinal mucosa [42]. The gut plays an important 
role in the infectious and septic complications 
observed in clinical conditions [43]. NO is 
important in mucosal defence in that it influences 
virtually every component of mucosal defence and 
can influence gastrointestinal mucosal integrity 
through actions on many cells [15]. In this study 
we found that inhibition of NO increased the 
incidence and the number of the translocated 
bacteria, at all time intervals, to the extraintestinal 
sites. Other studies showed that inhibition of NO 
with L-NAME causes a rapid increase in mucosal 
permeability to 
51Cr-EDTA [12]. NO inhibition also 
activates mast cells in the mucosa and 
consequently increases epithelial permeability 
[44]. Synthesis of NO from L-arginine has an 
important role in maintaining the integrity of the 
intestinal mucosa following acute challenge with 
LPS and it has been suggested that endogenous 
NO has an important acute protective role in the 
intestinal microvasculature against blood-born 
toxins and tissue destructive mediators [10]. The 
reported increased intestinal permeability by NO 
inhibition could explain the increased incidence 
and number of translocating bacteria. It is 
plausible that increased bacterial translocation due 
to the inhibition of NO was one of the factors 
potentiating the liver injury and failure in this liver 
injury model. Most bacterial infections in critically ill 
or immunocompromised patients are caused by 
the patients own microflora and many patients 
dying of sepsis or multiple system organ failure 
have enteric bacteraemia for which no septic 
focus is identified, indicating that these infections 
may have originated from the gut [45]. NO is a 
potent mediator of antimicrobial defence 
mechanism [46] and the reactive nitrogen 
intermediates contribute to the ability of activated 
rodent macrophages to inhibit a wide variety of 
intracellular and extra cellular pathogens [47]. The 
inhibition of NO production was associated with 
impaired chemotaxis in polymorphonuclear 
leukocytes [48]. The increased incidence of 
bacterial translocation in our study could also be 
due to inhibition of NO antimicrobial effects. NO 
has multiple immunoregulatory and antimicrobial 
functions and it either kills or inhibits
 the replication 
of a wide variety of pathogens including viruses, 
bacteria,
 parasites, and fungi. The effect of inhaled 
NO on infections in humans is just beginning
 to be 
evaluated [49]. 
The inhibition of NO in our study increased 
significantly the Enterobacteriaceae count in both 
cecum and colon and the G-negative anaerobes in 
the colon. It has been previously shown that NO 
inhibits a wide variety of intracellular and extra-
cellular pathogens [47]. It seems that NO inhibition 
disturbed the intestinal microflora by increasing 
the bacterial count especially the potentially 
pathogenic organisms. An increased translocation 
of these bacteria may add more damage to the 
liver and reduce capacity for the clearance of 
translocated bacteria, with increased risk of 
sepsis, septic syndrome and multiple system 
organ failure. We did not observe any endotoxin 
levels in the experimental groups; variable 
amounts of bilirubin in the samples could have 
masked the presence of small amount of 
endotoxins in the chromogenic assay and make its 
detection difficult. Similar to our finding, Al-Tuwaijri 
et al [50] did not detect any systemic endotoxin 
level after induction of liver injury by D-
galactosamine, as well as normal control animals. 
We have shown previously that lactulose, with its 
known anti-endotoxin activity, significantly 
improved the liver cell damage in the D-
galactosamine acute liver injury model [51]. This 
could indicate a role for endotoxin in the liver 
injury. In our study we have used the D-
galactosamine model without exogenous 
administration of LPS. There are evidences that 
implicate gut-derived endotoxin in the 
pathogenesis of D-galactosamine induced hepatic 
injury [52]. If the colon is removed before 
challenge with D-galactosamine, hepatic injury is 
greatly reduced [53]. It has been shown that 
severely disturbed gut flora in rats with D-
galactosamine-induced acute liver failure plays an 
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important role in the elevation of endotoxin level in 
the portal vein [54]. High portal level of LPS could 
lead to a pronounced secretion of pro-
inflammatory mediators by Kupffer cell and 
ultimately to endotoxin-induced liver injury [54,55]. 
Some other researchers have used D-
galactosamine + exogenous LPS which produce a 
more severe injury and the role of nitric oxide] in 
that model need to be studied. 
NO protection on the liver could be due to 
increased blood flow, inhibition of platelet 
aggregation and adhesion, inhibition of intra-
hepatic thrombosis and scavenging of superoxide 
and other oxygen free radicals. NO could also 
affect bacterial translocation by maintaining the 
intestinal mucosal integrity and through its 
antimicrobial activity against a wide variety of 
intracellular and extra-cellular pathogens. We 
therefore conclude that inhibition of NO in an acute 
liver injury model potentiates the liver injury as 
evidenced by increased appearance of 
hepatocellular necrosis and elevated liver 
enzymes and bilirubin. It increased the 
Enterobacteriaceae in both cecum and colon and 
G-negative anaerobes in the colon and increased 
bacterial translocation to extra-intestinal sites. The 
increased bacterial translocation could be one of 
the mechanisms to account for the potentiation of 
liver injury.  
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